Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
Volume
174.37 K
Value Traded
63.59 K
Short % Float
-
Days to Cover
4.0
+1.57%Week
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
89.61 M
EPS (TTM)
-0.09
P/E Ratio
-
Ent. Value
24.07 M
Total Shares
243.70 M
Float Shares
-
Insiders
-
Institutions
-
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
VXRT Catalyst Timeline
Dated clinical, regulatory and corporate events for Vaxart, Inc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Vaxart, Inc
10Total events
1Upcoming
1Tier-1 (high impact)
2025 to 2026Coverage
Upcoming catalysts 1
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 8
▲PublicationVXA-H5-02Presentation
Peer-reviewed publication of VXA-H5-02 preclinical H5N1 ferret study in Frontiers in Immunology
H5N1 avian influenzasource ↗
▲Preclinical PoCVXA-H5-02Preclinical
VXA-H5-02 conferred 100% protection against lethal H5N1 clade 2.3.4.4b challenge in ferrets
H5N1 avian influenzasource ↗
●R&D DayPresentation
Vaxart management to present at H.C. Wainwright 28th Annual Global Investment Conference
▲Topline ReadoutVXA-H5-02Clinical Data
Vaxart previously reported topline results from VXA-H5-02 preclinical H5N1 study
H5N1 avian influenzasource ↗
Past FDA Catalysts and PDUFA Decisions
How VXRT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | COVID-19 Vaccine | Phase 2 data readout | Phase 2b |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every VXRT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Watson W. MarkDirector | Buy | 10,000 134,125 held | $0.65 | 05/22/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VXRT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| SILVERARC CAPITAL MANAGEMENT, LLC | 0.1 % (-50 %) | 278.32 K | 683.83 K | -36.55% ( -393.96 K) |
Ownership Trends
VXRT Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
2.4M
Shares Sold Short
+0.5% vs prior count
4.0 Moderate
Days to Cover
trading days of normal volume to buy every short share back
611.6K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VXRT ranks across every disease it competes in
Competitive Position is a premium feature
See how VXRT ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVXRT News
-VXRT
Oct 29, 2026Vaxart to Host Stockholder Fireside Chat on November 6 at 4:30 p.m. ET
Vaxart, Inc. will host a virtual fireside chat on November 6, 2026, at 4:30 p.m. ET. The chat will address stockholder questions following the company's Q3 financial results report on November 5, 2026. Vaxart focuses on oral recombinant vaccines and aims to provide innovative solutions in immunization.
Read more →-VXRT
Oct 8, 2026Vaxart Announces Publication of Preclinical Study Demonstrating 100% Protection Against a Lethal Dose of H5N1 Avian Flu in a Ferret Challenge Model
Vaxart announced positive results from a preclinical study of its oral vaccine VXA-H5-02 against H5N1 avian flu. The study showed a 100% survival rate in ferrets after exposure to a lethal dose of the virus. Additionally, the vaccine significantly reduced viral load and elicited strong immune responses. These findings support the potential of Vaxart's oral vaccine platform for pandemic preparedness.
Read more →-VXRT
Sep 8, 2026Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Vaxart, Inc. announced its participation in the H.C. Wainwright 28th Annual Global Investment Conference from September 14-16, 2026. A management team member will present on September 14 from 1:00 p.m. to 1:30 p.m. ET. Investors can access a live webcast and schedule meetings with management during the event.
Read more →-VXRT
Jul 30, 2026▲ +9.2%on this news· ran to +24% by day 3
Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET
Vaxart, Inc. will host a virtual fireside chat on August 7, 2026, at 4:30 p.m. ET. This event follows the company's announcement to report its second quarter financial results on August 6, 2026. Investors can submit questions in advance and access the chat via Vaxart's website.
Read more →-VXRT
May 7, 2026Vaxart Provides Business Update and Reports First Quarter 2026 Financial Results
Topline data from 400-person sentinel cohort of the Phase 2b COVID-19 trial anticipated in Q2 2026 Cash, cash equivalents, and investments of $61.0 million as of March 31, 2026; runway into second quarter of 2027 Live stockholder fireside chat scheduled for May 8, 2026 at 4:30
Read more →-VXRT
Apr 17, 2026Vaxart Announces Share Purchase Agreement for up to $25 Million with Lincoln Park Capital
SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that it has entered into
Read more →-VXRT
Mar 4, 2026Vaxart to Host Upcoming Conference Calls
Vaxart, Inc. will host two upcoming conference calls, including a full year 2025 business update on March 12, 2026, and a stockholder fireside chat on March 13, 2026. The calls will provide financial results and allow investors to engage with management. The company focuses on developing oral vaccines using a proprietary delivery platform.
Read more →-VXRT
Sep 8, 2025Vaxart Announces Adjournment of Special Meeting of Stockholders
Vaxart has announced the adjournment of its special meeting of stockholders to September 19, 2025. This decision provides stockholders with additional time to consider proposals, including a reverse stock split. The company aims to maximize stockholder value and encourages participation in the voting process. The meeting will be held virtually, allowing stockholders to engage with the Board.
Read more →-VXRT
Aug 29, 2025▲ +8.3%on this news
Vaxart Granted Extension by Nasdaq to Regain Compliance
Vaxart, Inc. has been granted an extension by Nasdaq to regain compliance with its minimum bid price rule until October 17, 2025. The company must obtain stockholder approval for a reverse stock split by September 5, 2025, and complete it by October 6, 2025. Vaxart's management is actively communicating with stockholders to secure their support for this plan.
Read more →-VXRT
Aug 13, 2025Vaxart Provides Business Update and Reports Second Quarter 2025 Financial Results
Reported positive topline data from Phase 1 clinical trial evaluating Company’s second-generation oral norovirus vaccine constructs, supporting potential for improved protection against infection Enrolled approximately 5,000 participants in COVID-19 Phase 2b trial prior to stop
Read more →-VXRT
Aug 8, 2025Vaxart CEO Issues Letter to Stockholders
- Management Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on September 4, 2025 - SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology compan
Read more →-VXRT
Jul 24, 2025Vaxart Submits Proxy Statement for Reverse Stock Split to Support Resumption of Trading on Nasdaq
- Special Meeting of Stockholders to be Held Virtually on September 5, 2025 - - Live Stockholder Fireside Chat to be Scheduled to Answer Frequently Asked Stockholder Questions - - Nasdaq Hearings Panel Meeting Scheduled on August 14, 2025 - SOUTH SAN FRANCISCO, Calif., July 24
Read more →-VXRT
Jul 8, 2025Vaxart Announces Trading on OTCQX Best Market
SOUTH SAN FRANCISCO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today announced its commo
Read more →-VXRT
May 29, 2025Vaxart’s Founder and Chief Scientific Officer Provides Video Update to Stockholders
Dr. Sean Tucker, Founder and CSO of Vaxart, Urges Stockholders to Vote FOR Reverse Stock Split Proposal by 11:59 p.m. Eastern Time on June 1, 2025 Company Corrects Record on Common Misconceptions Regarding the Reverse Stock Split Proposal SOUTH SAN FRANCISCO, Calif., May 29, 20
Read more →-VXRT
May 21, 2025▼ -10%on this news
Vaxart Announces Adjournment of Annual Meeting of Stockholders
Meeting adjourned to June 2, 2025 at 8:30 a.m. Pacific Time Vaxart encourages all stockholders of record on March 26, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on June 1, 2025 SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nas
Read more →-VXRT
May 20, 2025Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors approved certain equity awards to the Company’s new Chief Financial Officer, Jeroen Gras
Read more →-VXRT
May 16, 2025▲ +19%on this newsshared move
Vaxart Approves Resolutions to Narrow Proposed Reverse Split Range and Proposes Reducing Authorized Shares at Future Stockholder Meeting
Company Urges Stockholders to Vote ‘FOR’ Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Vaxart, In
Read more →-VXRT
May 13, 2025Vaxart Provides Business Update and Reports First Quarter 2025 Financial Results
Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company’s second-generation oral norovirus vaccine constructs, with topline data expecte
Read more →-VXRT
May 12, 2025Vaxart Addresses Frequently Asked Questions on Reverse Stock Split Proposal in Definitive Proxy Statement
Company Urges Stockholders to Vote FOR Reverse Stock Split Proposal at Upcoming Annual Meeting to Avoid Nasdaq Delisting SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today addresses frequently asked stockholder questions regarding a r
Read more →About Vaxart, Inc
BIOPHARMAWATCH ELITE
Trade the next VXRT catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime